Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto) for High Risk People With Mild COVID-19

Next Previous
X
Search
Trial Profile

A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto) for High Risk People With Mild COVID-19

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Multivitamin
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 23 Nov 2023 Results of meta-analysis from NCT04504032 and NCT04508023 study analyzing antithrombotic prophylaxis with rivaroxaban in patients with prehospital COVID-19, published in the Thrombosis and Haemostasis
    • 15 Sep 2021 Primary endpoint (Proportion of Participants With Disease Progression) has not been met, as per results published in the Clinical Infectious Diseases.
    • 15 Sep 2021 Results assessing safety and efficacy of rivaroxaban in high-risk adults with mild COVID-19, published in the Clinical Infectious Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top